408 related articles for article (PubMed ID: 32307307)
1. Immunogenicity and safety of a DTaP-IPV/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan.
Nakayama T; Vidor E; Tsuzuki D; Nishina S; Sasaki T; Ishii Y; Mizukami H; Tsuge H
J Infect Chemother; 2020 Jul; 26(7):651-659. PubMed ID: 32307307
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
Klein NP; Abu-Elyazeed R; Cheuvart B; Janssens W; Mesaros N
Hum Vaccin Immunother; 2019; 15(4):809-821. PubMed ID: 30444673
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
4. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
5. Disparate kinetics in immune response of two different
Martinón-Torres F; Salamanca de la Cueva I; Horn M; Westerholt S; Bosis S; Meyer N; Cheuvart B; Virk N; Jakes RW; Duchenne M; Van den Steen P
Hum Vaccin Immunother; 2024 Dec; 20(1):2342630. PubMed ID: 38687024
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants.
Li Y; Li RC; Ye Q; Li C; Liu YP; Ma X; Li Y; Zhao H; Chen X; Assudani D; Karkada N; Han HH; Van Der Meeren O; Mesaros N
Hum Vaccin Immunother; 2017 Mar; 13(3):588-598. PubMed ID: 27768515
[TBL] [Abstract][Full Text] [Related]
7. Antibody persistence to diphtheria toxoid, tetanus toxoid,
Wanlapakorn N; Sarawanangkoor N; Srimuan D; Thatsanathorn T; Thongmee T; Poovorawan Y
Hum Vaccin Immunother; 2024 Dec; 20(1):2352909. PubMed ID: 38752802
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations.
Schmitt HJ; Zepp F; Müschenborn S; Sümenicht G; Schuind A; Beutel K; Knuf M; Bock HL; Bogaerts H; Clemens R
Eur J Pediatr; 1998 Mar; 157(3):208-14. PubMed ID: 9537487
[TBL] [Abstract][Full Text] [Related]
9. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
[TBL] [Abstract][Full Text] [Related]
11. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
[TBL] [Abstract][Full Text] [Related]
12. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
13. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
López P; Arguedas Mohs A; Abdelnour Vásquez A; Consuelo-Miranda M; Feroldi E; Noriega F; Jordanov E; B Chir S; Zambrano B
Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500
[TBL] [Abstract][Full Text] [Related]
15. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and Safety of a Booster Injection of DTap-IPV//Hib (Pentaxim) Administered Concomitantly With Tetravalent Dengue Vaccine in Healthy Toddlers 15-18 Months of Age in Mexico: A Randomized Trial.
Melo FIR; Morales JJR; De Los Santos AHM; Rivas E; Vigne C; Noriega F
Pediatr Infect Dis J; 2017 Jun; 36(6):602-608. PubMed ID: 28067718
[TBL] [Abstract][Full Text] [Related]
18. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Johns TL; Hutter GE
Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
[TBL] [Abstract][Full Text] [Related]
19. Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis/Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination.
Rennels MB; Englund JA; Bernstein DI; Losonsky GA; Anderson EL; Pichichero ME; Munoz FM; Wolff MC
Pediatr Infect Dis J; 2000 May; 19(5):417-23. PubMed ID: 10819337
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants.
Lee CY; Thipphawong J; Huang LM; Lee PI; Chiu HH; Lin W; Debois H; Harrison D; Xie F; Barreto L
Pediatrics; 1999 Jan; 103(1):25-30. PubMed ID: 9917435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
